Angiomotin family proteins in the Hippo signaling pathway.
Hippo
angiogenesis
angiomotin
cancer
Journal
BioEssays : news and reviews in molecular, cellular and developmental biology
ISSN: 1521-1878
Titre abrégé: Bioessays
Pays: United States
ID NLM: 8510851
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
revised:
03
05
2024
received:
01
04
2024
accepted:
08
05
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
aheadofprint
Résumé
The Motin family proteins (Motins) are a class of scaffolding proteins consisting of Angiomotin (AMOT), AMOT-like protein 1 (AMOTL1), and AMOT-like protein 2 (AMOTL2). Motins play a pivotal role in angiogenesis, tumorigenesis, and neurogenesis by modulating multiple cellular signaling pathways. Recent findings indicate that Motins are components of the Hippo pathway, a signaling cascade involved in development and cancer. This review discusses how Motins are integrated into the Hippo signaling network, as either upstream regulators or downstream effectors, to modulate cell proliferation and migration. The repression of YAP/TAZ by Motins contributes to growth inhibition, whereas subcellular localization of Motins and their interactions with actin fibers are critical in regulating cell migration. The net effect of Motins on cell proliferation and migration may contribute to their diverse biological functions.
Identifiants
pubmed: 38760875
doi: 10.1002/bies.202400076
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2400076Subventions
Organisme : National Key R&D Program of China
ID : 2018YFA0800304
Organisme : National Key R&D Program of China
ID : 2020YFA0803202
Organisme : National Natural Science Foundation of China
ID : 32200570
Organisme : National Natural Science Foundation of China
ID : 32370770
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 21S11905000
Organisme : Shanghai Municipal Health Commission
ID : 2022XD049
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Troyanovsky, B., Levchenko, T., Månsson, G., Matvijenko, O., & Holmgren, L. (2001). Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. Journal of Cell Biology, 152, 1247–1254.
Ernkvist, M., Aase, K., Ukomadu, C., Wohlschlegel, J., Blackman, R., Veitonmäki, N., Bratt, A., Dutta, A., & Holmgren, L. (2006). p130‐angiomotin associates to actin and controls endothelial cell shape. FEBS Journal, 273, 2000–2011.
Bratt, A., Wilson, W. J., Troyanovsky, B., Aase, K., Kessler, R., Meir, E. G. V., & Holmgren, L. (2002). Angiomotin belongs to a novel protein family with conserved coiled‐coil and PDZ binding domains. Gene, 298, 69–77.
Nishimura, M., Kakizaki, M., Ono, Y., Morimoto, K., Takeuchi, M., Inoue, Y., Imai, T., & Takai, Y. (2002). JEAP, a novel component of tight junctions in exocrine cells. Journal of Biological Chemistry, 277, 5583–5587.
Hultin, S., Zheng, Y., Mojallal, M., Vertuani, S., Gentili, C., Balland, M., Milloud, R., Belting, H.‐G., Affolter, M., Helker, C. S. M., Adams, R. H., Herzog, W., Uhlen, P., Majumdar, A., & Holmgren, L. (2014). AmotL2 links VE‐cadherin to contractile actin fibres necessary for aortic lumen expansion. Nature Communications, 5, 3743.
Amirifar, P., & Kissil, J. (2023). The role of Motin family proteins in tumorigenesis‐an update. Oncogene, 42, 1265–1271.
Moleirinho, S., Guerrant, W., & Kissil, J. L. (2014). The Angiomotins–from discovery to function. FEBS Letters, 588, 2693–2703.
Moreau, J., Lord, M., Boucher, M., Belleau, P., & Fernandes, M. J. G. (2005). Protein diversity is generated within the motin family of proteins by alternative pre‐mRNA splicing. Gene, 350, 137–148.
Heller, B., Adu‐Gyamfi, E., Smith‐Kinnaman, W., Babbey, C., Vora, M., Xue, Y., Bittman, R., Stahelin, R. V., & Wells, C. D. (2010). Amot recognizes a juxtanuclear endocytic recycling compartment via a novel lipid binding domain. Journal of Biological Chemistry, 285, 12308–12320.
Chan, S. W., Lim, C. J., Chong, Y. F., Pobbati, A. V., Huang, C., & Hong, W. (2011). Hippo pathway‐independent restriction of TAZ and YAP by angiomotin. Journal of Biological Chemistry, 286, 7018–7026.
Wang, W., Huang, J., & Chen, J. (2011). Angiomotin‐like proteins associate with and negatively regulate YAP1. Journal of Biological Chemistry, 286, 4364–4370.
Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C.‐Y., Lei, Q., & Guan, K.‐L. (2011). Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes & Development, 25, 51–63.
Wang, W., Li, N., Li, X., Tran, M. K, Han, X., & Chen, J. (2015). Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Reports, 13, 524–532.
Dai, X., She, P., Chi, F., Feng, Y., Liu, H., Jin, D., Zhao, Y., Guo, X., Jiang, D., Guan, K.‐L., Zhong, T. P., & Zhao, B. (2013). Phosphorylation of angiomotin by Lats1/2 kinases inhibits F‐actin binding, cell migration, and angiogenesis. Journal of Biological Chemistry, 288, 34041–34051.
Adler, J. J., Johnson, D. E., Heller, B. L., Bringman, L. R., Ranahan, W. P., Conwell, M. D., Sun, Y., Hudmon, A., & Wells, C. D. (2013). Serum deprivation inhibits the transcriptional co‐activator YAP and cell growth via phosphorylation of the 130‐kDa isoform of Angiomotin by the LATS1/2 protein kinases. PNAS, 110, 17368–17373.
Chan, S. W., Lim, C. J., Guo, F., Tan, I., Leung, T., & Hong, W. (2013). Actin‐binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway‐mediated phosphorylation. Journal of Biological Chemistry, 288, 37296–37307.
Mana‐Capelli, S., Paramasivam, M., Dutta, S., & Mccollum, D. (2014). Angiomotins link F‐actin architecture to Hippo pathway signaling. Molecular Biology of the Cell, 25, 1676–1685.
Hirate, Y., Hirahara, S., Inoue, K.‐I., Suzuki, A., Alarcon, V. B., Akimoto, K., Hirai, T., Hara, T., Adachi, M., Chida, K., Ohno, S., Marikawa, Y., Nakao, K., Shimono, A., & Sasaki, H. (2013). Polarity‐dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Current Biology, 23, 1181–1194.
Wang, Y., Zhu, Y., Wang, Y., Chang, Y., Geng, F., Ma, M., Gu, Y., Yu, A., Zhu, R., Yu, P., Sha, Z., Qi, S., Li, J., Zhao, W., Pan, W., Zhang, R., & Yu, F.‐X. (2023). Proteolytic activation of angiomotin by DDI2 promotes angiogenesis. Embo Journal, 42, e112900.
Mercenne, G., Alam, S. L., Arii, J., Lalonde, M. S., & Sundquist, W. I. (2015). Angiomotin functions in HIV‐1 assembly and budding. Elife, 4, e03778.
Wang, C., An, J., Zhang, P., Xu, C., Gao, K., Wu, D., Wang, D., Yu, H., Liu, J. O., & Yu, L. (2012). The Nedd4‐like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin‐dependent degradation. Biochemical Journal, 444, 279–289.
Rheinemann, L., Thompson, T., Mercenne, G., Paine, E. L., Peterson, F. C., Volkman, B. F., Alam, S. L., Alian, A., & Sundquist, W. I. (2021). Interactions between AMOT PPxY motifs and NEDD4L WW domains function in HIV‐1 release. Journal of Biological Chemistry, 297, 100975.
Adler, J. J., Heller, B. L., Bringman, L. R., Ranahan, W. P., Cocklin, R. R., Goebl, M. G., Oh, M., Lim, H.‐S., Ingham, R. J., & Wells, C. D. (2013). Amot130 adapts atrophin‐1 interacting protein 4 to inhibit yes‐associated protein signaling and cell growth. Journal of Biological Chemistry, 288, 15181–15193.
Wang, Y., Zhu, Y., Gu, Y., Ma, M., Wang, Y., Qi, S., Zeng, Y., Zhu, R., Wang, X., Yu, P., Xu, J., Shu, Y., & Yu, F.‐X. (2021). Stabilization of Motin family proteins in NF2‐deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. Cell Reports, 36, 109596.
Troilo, A., Benson, E. K., Esposito, D., Garibsingh, R.‐A. A., Reddy, E. P, Mungamuri, S. K., & Aaronson, S. A. (2016). Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD‐dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget, 7, 28765–28782.
Campbell, C. I., Samavarchi‐Tehrani, P., Barrios‐Rodiles, M., Datti, A., Gingras, A. C., & Wrana, J. L. (2016). The RNF146 and tankyrase pathway maintains the junctional Crumbs complex through regulation of angiomotin. Journal of Cell Science, 129, 3396–3411.
Wang, H., Lu, B., Castillo, J., Zhang, Y., Yang, Z., Mcallister, G., Lindeman, A., Reece‐Hoyes, J., Tallarico, J., Russ, C., Hoffman, G., Xu, W., Schirle, M., & Cong, F. (2016). Tankyrase inhibitor sensitizes lung cancer cells to endothelial growth factor receptor (EGFR) Inhibition via stabilizing angiomotins and inhibiting YAP signaling. Journal of Biological Chemistry, 291, 15256–15266.
Darosa, P. A., Wang, Z., Jiang, X., Pruneda, J. N., Cong, F., Klevit, R. E., & Xu, W. (2015). Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP‐ribosyl)ation signal. Nature, 517, 223–226.
Zhang, Y., Liu, S., Mickanin, C., Feng, Y., Charlat, O., Michaud, G. A., Schirle, M., Shi, X., Hild, M., Bauer, A., Myer, V. E., Finan, P. M., Porter, J. A., Huang, S.‐M. A., & Cong, F. (2011). RNF146 is a poly(ADP‐ribose)‐directed E3 ligase that regulates axin degradation and Wnt signalling. Nature Cell Biology, 13, 623–629.
Kang, H. C., Lee, Y.‐Il., Shin, J.‐H., Andrabi, S. A., Chi, Z., Gagné, J.‐P., Lee, Y., Ko, H. S., Lee, B. D., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2011). Iduna is a poly(ADP‐ribose) (PAR)‐dependent E3 ubiquitin ligase that regulates DNA damage. PNAS, 108, 14103–14108.
Callow, M. G., Tran, H., Phu, L., Lau, T., Lee, J., Sandoval, W. N., Liu, P. S., Bheddah, S., Tao, J., Lill, J. R., Hongo, J.‐A., Davis, D., Kirkpatrick, D. S., Polakis, P., & Costa, M. (2011). Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS ONE, 6, e22595.
Wells, C. D., Fawcett, J. P., Traweger, A., Yamanaka, Y., Goudreault, M., Elder, K., Kulkarni, S., Gish, G., Virag, C., Lim, C., Colwill, K., Starostine, A., Metalnikov, P., & Pawson, T. (2006). A Rich1/Amot complex regulates the Cdc42 GTPase and apical‐polarity proteins in epithelial cells. Cell, 125, 535–548.
Ernkvist, M., Persson, N. L., Audebert, S., Lecine, P., Sinha, I., Liu, M., Schlueter, M., Horowitz, A., Aase, K., Weide, T., Borg, J.‐P., Majumdar, A., & Holmgren, L. (2009). The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells. Blood, 113, 244–253.
Bratt, A., Birot, O., Sinha, I., Veitonmäki, N., Aase, K., Ernkvist, M., & Holmgren, L. (2005). Angiomotin regulates endothelial cell‐cell junctions and cell motility. Journal of Biological Chemistry, 280, 34859–34869.
Kantar, D., Mur, E. B., Mancini, M., Slaninova, V., Salah, Y. B., Costa, L., Forest, E., Lassus, P., Géminard, C., Boissière‐Michot, F., Orsetti, B., Theillet, C., Colinge, J., Benistant, C., Maraver, A., Heron‐Milhavet, L., & Djiane, A. (2021). MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis. Scientific Reports, 11, 5752.
Yi, C., Troutman, S., Fera, D., Stemmer‐Rachamimov, A., Avila, J. L., Christian, N., Persson, N. L., Shimono, A., Speicher, D. W., Marmorstein, R., Holmgren, L., & Kissil, J. L. (2011). A tight junction‐associated Merlin‐angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell, 19, 527–540.
Wu, C., Agrawal, S., Vasanji, A., Drazba, J., Sarkaria, S., Xie, J., Welch, C. M., Liu, M., Anand‐Apte, B., & Horowitz, A. (2011). Rab13‐dependent trafficking of RhoA is required for directional migration and angiogenesis. Journal of Biological Chemistry, 286, 23511–23520.
Garnaas, M. K., Moodie, K. L., Liu, M.‐L., Samant, G. V., Li, K., Marx, R., Baraban, J. M., Horowitz, A., & Ramchandran, R. (2008). Syx, a RhoA guanine exchange factor, is essential for angiogenesis in Vivo. Circulation Research, 103, 710–716.
Ranahan, W. P., Han, Z., Smith‐Kinnaman, W., Nabinger, S. C., Heller, B., Herbert, B.‐S., Chan, R., & Wells, C. D. (2011). The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal‐regulated kinases. Cancer Research, 71, 2203–2211.
Wang, Y., Li, Z., Xu, P., Huang, L., Tong, J., Huang, H., & Meng, A. (2011). Angiomotin‐like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis. Journal of Biological Chemistry, 286, 41095–41104.
Brunner, P., Hastar, N., Kaehler, C., Burdzinski, W., Jatzlau, J., & Knaus, P. (2020). AMOT130 drives BMP‐SMAD signaling at the apical membrane in polarized cells. Molecular Biology of the Cell, 31, 118–130.
Li, Z., Wang, Y., Zhang, M., Xu, P., Huang, H., Wu, D., & Meng, A. (2012). The Amotl2 gene inhibits Wnt/beta‐catenin signaling and regulates embryonic development in zebrafish. Journal of Biological Chemistry, 287, 13005–13015.
Wigerius, M., Quinn, D., & Fawcett, J. P. (2020). Emerging roles for angiomotin in the nervous system. Science Signaling, 13, https://doi.org/10.1126/scisignal.abc0635
Hong, W. (2013). Angiomotin'g YAP into the nucleus for cell proliferation and cancer development. Science Signaling, 6, pe27.
Zhong, Z., Meng, Z., & Yu, F.‐X. (2023). Reconstructing the Hippo signaling network. Sci Bull (Beijing), 68, 2307–2310.
Qi, S., Zhong, Z., Zhu, Y., Wang, Y., Ma, M., Wang, Y., Liu, X., Jin, R., Jiao, Z., Zhu, R., Sha, Z., Dang, K., Liu, Y., Lim, D.‐S., Mao, J., Zhang, L., & Yu, F.‐X. (2023). Two Hippo signaling modules orchestrate liver size and tumorigenesis. Embo Journal, 42, e112126.
Qi, S., Zhu, Y., Liu, X., Li, P., Wang, Y., Zeng, Y., Yu, A., Wang, Y., Sha, Z., Zhong, Z., Zhu, R., Yuan, H., Ye, D., Huang, S., Ling, C., Xu, Y., Zhou, D., Zhang, L., & Yu, F.‐X. (2022). WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. Molecular Cell, 82, 1850–1864.e7.
Johnson, R., & Halder, G. (2014). The two faces of Hippo, targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discovery, 13, 63–79.
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014). The biology of YAP/TAZ, hippo signaling and beyond. Physiological Reviews, 94, 1287–1312.
Yu, F.‐X., Zhao, B., & Guan, K.‐L. (2015). Hippo Pathway in organ size control, tissue homeostasis, and cancer. Cell, 163, 811–828.
Zheng, Y., & Pan, D. (2019). The Hippo signaling pathway in development and disease. Developmental Cell, 50, 264–282.
Zhong, Z., Jiao, Z., & Yu, F.‐X. (2024). The Hippo signaling pathway in development and regeneration. Cell Reports, 43, 113926.
Leung, C. Y., & Zernicka‐Goetz, M. (2013). Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway‐dependent and ‐independent mechanisms. Nature Communications, 4, 2251.
Liu, M., Yan, M., Lv, H., Wang, B., Lv, X., Zhang, H., Xiang, S., Du, J., Liu, T., Tian, Y., Zhang, X., Zhou, F., Cheng, T., Zhu, Y., Jiang, H., Cao, Y., & Ai, D. (2020). Macrophage K63‐linked ubiquitination of YAP promotes its nuclear localization and exacerbates atherosclerosis. Cell reports, 32, 107990.
Moleirinho, S., Hoxha, S., Mandati, V., Curtale, G., Troutman, S., Ehmer, U., & Kissil, J. L. (2017). Regulation of localization and function of the transcriptional co‐activator YAP by angiomotin. Elife, 6, e23966.
Deran, M., Yang, J., Shen, C.‐H., Peters, E. C., Fitamant, J., Chan, P., Hsieh, M., Zhu, S., Asara, J. M., Zheng, B., Bardeesy, N., Liu, J., & Wu, X. (2014). Energy stress regulates hippo‐YAP signaling involving AMPK‐mediated regulation of angiomotin‐like 1 protein. Cell Reports, 9, 495–503.
Yi, C., Shen, Z., Stemmer‐Rachamimov, A., Dawany, N., Troutman, S., Showe, L. C., Liu, Q., Shimono, A., Sudol, M., Holmgren, L., Stanger, B. Z., & Kissil, J. L. (2013). The p130 isoform of angiomotin is required for Yap‐mediated hepatic epithelial cell proliferation and tumorigenesis. Science Signaling, 6, ra77.
Lv, M., Li, S., Luo, C., Zhang, X., Shen, Y., Sui, Y., Wang, F., Wang, X., Yang, J., Liu, P., & Yang, J. (2016). Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP. Oncotarget, 7, 12393–12403.
Li, L., & Fan, C.‐M. (2017). A CREB‐MPP7‐AMOT regulatory axis controls muscle stem cell expansion and self‐renewal competence. Cell reports, 21, 1253–1266.
Zhang, Y., Yuan, J., Zhang, X., Yan, F., Huang, M., Wang, T., Zheng, X., & Zhang, M. (2016). Angiomotin promotes the malignant potential of colon cancer cells by activating the YAP‐ERK/PI3K‐AKT signaling pathway. Oncology Reports, 36, 3619–3626.
Mana‐Capelli, S., & Mccollum, D. (2018). Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. Journal of Biological Chemistry, 293, 18230–18241.
Paramasivam, M., Sarkeshik, A., Yates, J. R., Fernandes, M. J. G., & Mccollum, D. (2011). Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Molecular Biology of the Cell, 22, 3725–3733.
Li, Y., Zhou, H., Li, F., Chan, S. W., Lin, Z., Wei, Z., Yang, Z., Guo, F., Lim, C. J., Xing, W., Shen, Y., Hong, W., Long, J., & Zhang, M. (2015). Angiomotin binding‐induced activation of Merlin/NF2 in the Hippo pathway. Cell Research, 25, 801–817.
Couderc, C., Boin, A., Fuhrmann, L., Vincent‐Salomon, A., Mandati, V., Kieffer, Y., Mechta‐Grigoriou, F., Del Maestro, L., Chavrier, P., Vallerand, D., Brito, I., Dubois, T., De Koning, L., Bouvard, D., Louvard, D., Gautreau, A., & Lallemand, D. (2016). AMOTL1 promotes breast cancer progression and is antagonized by merlin. Neoplasia, 18, 10–24.
Shi, X., Yin, Z., Ling, B., Wang, L., Liu, C., Ruan, X., Zhang, W., & Chen, L. (2017). Rho differentially regulates the Hippo pathway by modulating the interaction between Amot and Nf2 in the blastocyst. Development (Cambridge, England), 144, 3957–3967.
Hwang, D., Kim, M., Kim, S., Kwon, M. R., Kang, Y.‐S., Kim, D., Kang, H.‐C., & Lim, D.‐S. (2021). AMOTL2 mono‐ubiquitination by WWP1 promotes contact inhibition by facilitating LATS activation. Life Sci Alliance, 4, e202000953.
Zhao, B., Li, L., Wang, L., Wang, C.‐Y., Yu, J., & Guan, K.‐L. (2012). Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes & Development, 26, 54–68.
Sansores‐Garcia, L., Bossuyt, W., Wada, K.‐I., Yonemura, S., Tao, C., Sasaki, H., & Halder, G. (2011). Modulating F‐actin organization induces organ growth by affecting the Hippo pathway. Embo Journal, 30, 2325–2335.
Wada, K.‐I., Itoga, K., Okano, T., Yonemura, S., & Sasaki, H. (2011). Hippo pathway regulation by cell morphology and stress fibers. Development (Cambridge, England), 138, 3907–3914.
Wang, L., Choi, K., Su, T., Li, B., Wu, X., Zhang, R., Driskill, J. H., Li, H., Lei, H., Guo, P., Chen, E. H., Zheng, Y., & Pan, D. (2022). Multiphase coalescence mediates Hippo pathway activation. Cell, 185, 4376–4393.e18.
Dai, X., Liu, H., Shen, S., Guo, X., Yan, H., Ji, X., Li, L., Huang, J., Feng, X.‐H., & Zhao, B. (2017). YAP activates the Hippo pathway in a negative feedback loop. Cell Research, 27, 1073.
Badouel, C., Gardano, L., Amin, N., Garg, A., Rosenfeld, R., Le Bihan, T., & Mcneill, H. (2009). The FERM‐domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. Developmental Cell, 16, 411–420.
Shimono, A., & Behringer, R. R. (2003). Angiomotin regulates visceral endoderm movements during mouse embryogenesis. Current Biology, 13, 613–617.
Aase, K., Ernkvist, M., Ebarasi, L., Jakobsson, L., Majumdar, A., Yi, C., Birot, O., Ming, Y., Kvanta, A., Edholm, D., Aspenström, P., Kissil, J., Claesson‐Welsh, L., Shimono, A., & Holmgren, L. (2007). Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes & Development, 21, 2055–2068.
Ernkvist, M., Birot, O., Sinha, I., Veitonmaki, N., Nyström, S., Aase, K., & Holmgren, L. (2008). Differential roles of p80‐ and p130‐angiomotin in the switch between migration and stabilization of endothelial cells. Biochimica Et Biophysica Acta, 1783, 429–437.
Ortiz, A., Lee, Y.‐C., Yu, G., Liu, H.‐C., Lin, S.‐C., Bilen, M. A., Cho, H., Yu‐Lee, L.‐Y., & Lin, S.‐H. (2015). Angiomotin is a novel component of cadherin‐11/beta‐catenin/p120 complex and is critical for cadherin‐11‐mediated cell migration. FASEB Journal, 29, 1080–1091.
Zheng, Y., Vertuani, S., Nyström, S., Audebert, S., Meijer, I., Tegnebratt, T., Borg, J.‐P., Uhlén, P., Majumdar, A., & Holmgren, L. (2009). Angiomotin‐like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis. Circulation Research, 105, 260–270.
Zheng, Y., Zhang, Y., Barutello, G., Chiu, K., Arigoni, M., Giampietro, C., Cavallo, F., & Holmgren, L. (2016). Angiomotin like‐1 is a novel component of the N‐cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis. Scientific Reports, 6, 30622.
Choi, K.‐S., Choi, H.‐J., Lee, J.‐K., Im, S., Zhang, H., Jeong, Y., Park, J. A., Lee, I.‐K., Kim, Y.‐M., & Kwon, Y.‐G. (2016). The endothelial E3 ligase HECW2 promotes endothelial cell junctions by increasing AMOTL1 protein stability via K63‐linked ubiquitination. Cell Signalling, 28, 1642–1651.
Hultin, S., Subramani, A., Hildebrand, S., Zheng, Y., Majumdar, A., & Holmgren, L. (2017). AmotL2 integrates polarity and junctional cues to modulate cell shape. Scientific Reports, 7, 7548.
Van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., Van Rooijen, M. A., Pradère, J. P., Pettit, T. R., Wakelam, M. J. O., Saulnier‐Blache, J. S., Mummery, C. L., Moolenaar, W. H., & Jonkers, J. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Molecular and Cellular Biology, 26, 5015–5022.
Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., Iwata, C., Miyazono, K., Sakimura, K., Shimizu, T., & Ishii, S. (2010). LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood, 116, 5060–5070.
Yukiura, H., Hama, K., Nakanaga, K., Tanaka, M., Asaoka, Y., Okudaira, S., Arima, N., Inoue, A., Hashimoto, T., Arai, H., Kawahara, A., Nishina, H., & Aoki, J. (2011). Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish. Journal of Biological Chemistry, 286, 43972–43983.
Huang, H., Lu, F.‐I., Jia, S., Meng, S., Cao, Y., Wang, Y., Ma, W., Yin, K., Wen, Z., Peng, J., Thisse, C., Thisse, B., & Meng, A. (2007). Amotl2 is essential for cell movements in zebrafish embryo and regulates c‐Src translocation. Development (Cambridge, England), 134, 979–988.
Zhang, Y., Zhang, Y., Kameishi, S., Barutello, G., Zheng, Y., Tobin, N. P., Nicosia, J., Hennig, K., Chiu, D. K.‐C., Balland, M., Barker, T. H., Cavallo, F., & Holmgren, L. (2021). The Amot/integrin protein complex transmits mechanical forces required for vascular expansion. Cell reports, 36, 109616.
Levchenko, T., Aase, K., Troyanovsky, B., Bratt, A., & Holmgren, L. (2003). Loss of responsiveness to chemotactic factors by deletion of the C‐terminal protein interaction site of angiomotin. Journal of Cell Science, 116, 3803–3810.
Park, J. A., & Kwon, Y.‐G. (2018). Hippo‐YAP/TAZ signaling in angiogenesis. BMB Rep, 51, 157–162.
Sakabe, M., Fan, J., Odaka, Y., Liu, N., Hassan, A., Duan, X., Stump, P., Byerly, L., Donaldson, M., Hao, J., Fruttiger, M., Lu, Q. R., Zheng, Y., Lang, R. A., & Xin, M. (2017). YAP/TAZ‐CDC42 signaling regulates vascular tip cell migration. PNAS, 114, 10918–10923.
Kim, J., Kim, Y. H., Kim, J., Park, D. Y., Bae, H., Lee, D.‐H., Kim, K. H., Hong, S. P., Jang, S. P., Kubota, Y., Kwon, Y.‐G., Lim, D.‐S., & Koh, G. Y. (2017). YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. Journal of Clinical Investigation, 127, 3441–3461.
Wang, X., Freire Valls, A., Schermann, G., Shen, Y., Moya, I. M., Castro, L., Urban, S., Solecki, G. M., Winkler, F., Riedemann, L., Jain, R. K., Mazzone, M., Schmidt, T., Fischer, T., Halder, G., & Ruiz De Almodóvar, C. (2017). YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Developmental Cell, 42, 462–478.e7.
Park, M. H., Kim, A. K., Manandhar, S., Oh, S. Y., Jang, G. H., Kang, L., Lee, D. W., Hyeon, D. Y., Lee, S. H., Lee, H. E., Huh, T. L., Suh, S. H., Hwang, D., Byun, K., Park, H. C., & Lee, Y. M. (2019). CCN1 interlinks integrin and hippo pathway to autoregulate tip cell activity. Elife, 8, e46012.
Moon, S., Lee, S., Caesar, J. A., Pruchenko, S., Leask, A., Knowles, J. A., Sinon, J., & Chaqour, B. (2020). A CTGF‐YAP regulatory pathway is essential for angiogenesis and barriergenesis in the retina. Iscience, 23, 101184.
Choi, H.‐J., Zhang, H., Park, H., Choi, K.‐S., Lee, H.‐W., Agrawal, V., Kim, Y.‐M., & Kwon, Y.‐G. (2015). Yes‐associated protein regulates endothelial cell contact‐mediated expression of angiopoietin‐2. Nature Communications, 6, 6943.
Min, J.‐K., Park, H., Choi, H.‐J., Kim, Y., Pyun, B.‐J., Agrawal, V., Song, B.‐W., Jeon, J., Maeng, Y.‐S., Rho, S.‐S., Shim, S., Chai, J.‐H., Koo, B.‐K., Hong, H. J., Yun, C.‐O., Choi, C., Kim, Y.‐M., Hwang, K.‐C., & Kwon, Y.‐G. (2011). The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells. Journal of Clinical Investigation, 121, 1882–1893.
Bae, J. H., Yang, M. J., Jeong, S.‐H., Kim, J., Hong, S. P., Kim, J. W., Kim, Y. H., & Koh, G. Y. (2022). Gatekeeping role of Nf2/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization. Science Advances, 8, eabn2611.
Moroishi, T., Park, H. W., Qin, B., Chen, Q., Meng, Z., Plouffe, S. W., Taniguchi, K., Yu, F.‐X., Karin, M., Pan, D., & Guan, K.‐L. (2015). A YAP/TAZ‐induced feedback mechanism regulates Hippo pathway homeostasis. Genes & Development, 29, 1271–1284.
Lv, M., Shen, Y., Yang, J., Li, S., Wang, B., Chen, Z., Li, P., Liu, P., & Yang, J. (2017). Angiomotin family members, oncogenes or tumor suppressors? International Journal of Biological Sciences, 13, 772–781.
Jiang, W. G., Watkins, G., Douglas‐Jones, A., Holmgren, L., & Mansel, R. E. (2006). Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer, 6, 16.
Zeng, H., Ortiz, A., Shen, P.‐F., Cheng, C.‐J., Lee, Y.‐C., Yu, G., Lin, S.‐C., Creighton, C. J., Yu‐Lee, L.‐Y., & Lin, S.‐H. (2017). Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo‐YAP pathway. Oncotarget, 8, 10145–10160.
Lin, X., Spindler, T. J., De Souza Fonseca, M. A., Corona, R. I., Seo, J.‐H., Dezem, F. S., Li, L., Lee, J. M., Long, H. W., Sellers, T. A., Karlan, B. Y., Noushmehr, H., Freedman, M. L., Gayther, S. A., & Lawrenson, K. (2019). Super‐enhancer‐associated LncRNA UCA1 interacts directly with AMOT to activate YAP target genes in epithelial ovarian cancer. Iscience, 17, 242–255.
Mojallal, M., Zheng, Y., Hultin, S., Audebert, S., Van Harn, T., Johnsson, P., Lenander, C., Fritz, N., Mieth, C., Corcoran, M., Lembo, F., Hallström, M., Hartman, J., Mazure, N. M., Weide, T., Grandér, D., Borg, J.‐P., Uhlén, P., & Holmgren, L. (2014). AmotL2 disrupts apical‐basal cell polarity and promotes tumour invasion. Nature Communications, 5, 4557.
Zhou, Y., Zhang, J., Li, H., Huang, T., Wong, C. C., Wu, F., Wu, M., Weng, N., Liu, L., Cheng, A. S. L., Yu, J., Wong, N., Lo, K. W., Tang, P. M. K., Kang, W., & To, K. F. (2020). AMOTL1 enhances YAP1 stability and promotes YAP1‐driven gastric oncogenesis. Oncogene, 39, 4375–4389.
Wang, Y., Justilien, V., Brennan, K. I., Jamieson, L., Murray, N. R., & Fields, A. P. (2017). PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene, 36, 534–545.
Hsu, Y.‐L., Hung, J.‐Y., Chou, S.‐H., Huang, M.‐S., Tsai, M.‐J., Lin, Y.‐S., Chiang, S.‐Y., Ho, Y.‐W., Wu, C.‐Y., & Kuo, P.‐L. (2015). Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene, 34, 4056–4068.
García‐Del Río, A., Prieto‐Fernández, E., Egia‐Mendikute, L., Antoñana‐Vildosola, A., Jimenez‐Lasheras, B., Lee, S. Y., Barreira‐Manrique, A., Zanetti, S. R., De Blas, A., Velasco‐Beltrán, P., Bosch, A., Aransay, A. M., & Palazon, A. (2023). Factor‐inhibiting HIF (FIH) promotes lung cancer progression. JCI Insight, 8, e167394.
Ye, S., Lawlor, M. A., Rivera‐Reyes, A., Egolf, S., Chor, S., Pak, K., Ciotti, G. E., Lee, A. C., Marino, G. E., Shah, J., Niedzwicki, D., Weber, K., Park, P. M. C., Alam, M. Z., Grazioli, A., Haldar, M., Xu, M., Perry, J. A., Qi, J., & Eisinger‐Mathason, T. S. K (2018). YAP1‐mediated suppression of USP31 enhances NFkappaB activity to promote sarcomagenesis. Cancer Research, 78, 2705–2720.
Liu, Y., Lu, Z., Shi, Y., & Sun, F. (2018). AMOT is required for YAP function in high glucose induced liver malignancy. Biochemical and Biophysical Research Communications, 495, 1555–1561.
Zhu, G., Chen, Y., Zhang, X., Wu, Q., Zhao, Y., Chen, Y., Sun, F., Qiao, Y., & Wang, J. (2017). 12‐O‐Tetradecanoylphorbol‐13‐acetate (TPA) is anti‐tumorigenic in liver cancer cells via inhibiting YAP through AMOT. Scientific Reports, 7, 44940.
Artinian, N., Cloninger, C., Holmes, B., Benavides‐Serrato, A., Bashir, T., & Gera, J. (2015). Phosphorylation of the Hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP signaling, resulting in enhanced glioblastoma growth and invasiveness. Journal of Biological Chemistry, 290, 19387–19401.
Yang, J., Zhang, X., Chen, Z., Shen, Y., Wang, F., Wang, Y., Liu, Y., Liu, P., & Yang, J. (2019). Angiomotin‐p130 inhibits beta‐catenin stability by competing with Axin for binding to tankyrase in breast cancer. Cell Death & Disease, 10, 179.
Chen, Z.‐L., Yang, J., Shen, Y.‐W., Li, S.‐T., Wang, X., Lv, M., Wang, B.‐Y., Li, P., Zhao, W., Qiu, R.‐Y., Liu, Y., Liu, P.‐J., & Yang, J. (2018). AmotP130 regulates Rho GTPase and decreases breast cancer cell mobility. Journal of Cellular and Molecular Medicine, 22, 2390–2403.
Cao, X., Pfaff, S. L., & Gage, F. H. (2008). YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes & Development, 22, 3320–3334.
Panciera, T., Azzolin, L., Fujimura, A., Di Biagio, D., Frasson, C., Bresolin, S., Soligo, S., Basso, G., Bicciato, S., Rosato, A., Cordenonsi, M., & Piccolo, S. (2016). Induction of expandable tissue‐specific stem/progenitor cells through transient expression of YAP/TAZ. Cell Stem Cell, 19, 725–737.
Lavado, A., Park, J. Y., Paré, J., Finkelstein, D., Pan, H., Xu, B., Fan, Y., Kumar, R. P., Neale, G., Kwak, Y. D., Mckinnon, P. J., Johnson, R. L., & Cao, X. (2018). The Hippo pathway prevents YAP/TAZ‐driven hypertranscription and controls neural progenitor number. Developmental Cell, 47, 576–591.e8.
Zaltsman, Y., Masuko, S., Bensen, J. J., & Kiessling, L. L. (2019). Angiomotin regulates YAP localization during neural differentiation of human pluripotent stem cells. Stem Cell Reports, 12, 869–877.
Kang, P. H., Schaffer, D. V., & Kumar, S. (2020). Angiomotin links ROCK and YAP signaling in mechanosensitive differentiation of neural stem cells. Molecular Biology of the Cell, 31, 386–396.
Rojek, K. O., Krzemień, J., Doleżyczek, H., Boguszewski, P. M., Kaczmarek, L., Konopka, W., Rylski, M., Jaworski, J., Holmgren, L., & Prószyński, T. J. (2019). Amot and Yap1 regulate neuronal dendritic tree complexity and locomotor coordination in mice. PLOS Biology, 17, e3000253.
Wigerius, M., Quinn, D., Diab, A., Clattenburg, L., Kolar, A., Qi, J., Krueger, S. R., & Fawcett, J. P. (2018). The polarity protein Angiomotin p130 controls dendritic spine maturation. Journal of Cell Biology, 217, 715–730.
Cao, R., Zhu, R., Sha, Z., Qi, S., Zhong, Z., Zheng, F., Lei, Y., Tan, Y., Zhu, Y., Wang, Y., Wang, Y., & Yu, F.‐X. (2023). WWC1/2 regulate spinogenesis and cognition in mice by stabilizing AMOT. Cell Death & Disease, 14, 491.